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Heart rate variabilityThe purpose of this study was to relate central inﬂammation to autonomic activity (heart rate variability (HRV))
in patients with rheumatoid arthritis (RA) and ﬁbromyalgia (FM). RA patients had reduced parasympathetic ac-
tivity and FM patients had increased sympathetic activity compared to healthy controls. Comparisons between
RA and FM showed higher cerebrospinal ﬂuid (CSF) interleukin (IL)-1β inversely correlated to parasympathetic
activity in RA. The FM patients had higher concentrations of CSF IL-8, IL-1Ra, IL-4 and IL-10, but none of these cy-
tokines correlated with HRV. In conclusion, we found different proﬁles of central cytokines, i.e., elevated IL-1β in
inﬂammatory pain (RA) and elevated IL-8 in dysfunctional pain (FM).
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Central nervous system (CNS) mechanisms such as central sensitiza-
tion, facilitation and disinhibition are involved in various forms of chronic
pain conditions. The latter was illustrated by ﬁndings of widespreadtoid arthritis; FM, ﬁbromyalgia;
kin 1 receptor antagonist; TNF,
d 2; BDNF, brain-derivedneuro-
COX-2, cyclooxygenase-2; ACR,
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I-20,Multidimensional Fatigue
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roscience, Karolinska Institute,
. This is an open access article underallodynia and hyperalgesia in patients with ﬁbromyalgia (FM) (dysfunc-
tional pain) (Kosek et al., 1996), but also other diseases characterized by
nociceptive and inﬂammatory pain, such as osteoarthritis (Kosek and
Ordeberg, 2000a,b; Gwilym et al., 2009; Arendt-Nielsen et al., 2010) and
rheumatoid arthritis (RA) (Lefﬂer et al., 2002). The mechanisms of sensi-
tization and hyperalgesia involve neuron interaction with activated glia
cells (for review see Watkins and Maier, 2005; Milligan and Watkins,
2009). Following activation, glia cells release pro-inﬂammatory cyto-
kines/chemokines such as tumor necrosis factor (TNF), interleukin-
1beta (IL-1β), interleukin-6 (IL-6) and interleukin-8 (IL-8), chemokine
(C–C motif) ligand 2 (CCL-2), also known as monocyte chemoattractant
protein 1 (MCP-1), as well as brain-derived neurotrophic factor (BDNF),
nerve growth factor (NGF), glutamate and substance P (SP) (Sofroniew
et al., 2001; Watkins and Maier, 2005; Milligan and Watkins, 2009),
substances with the potential for pain ampliﬁcation. Based on data from
animal studies, activated glia cells have been proposed to be an important
actor also for development and maintenance of chronic pain in humans
(Milligan and Watkins, 2009).
Supporting the role of neuroinﬂammation in human pain patients,
elevated cerebrospinal ﬂuid (CSF) concentrations of pro-inﬂammatory
cytokines/chemokines have been reported in patients with chronicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2004; Backonja et al., 2008) pain. In addition, we have previously docu-
mented increased CSF IL-8, but not IL-1β, in FM patients compared to
headache controls (Kadetoff et al., 2012) and increased CSF IL-1β levels
in patients with RA compared to surgical controls and to patients with
multiple sclerosis (MS), respectively (Lampa et al., 2012). These results
are in accordancewith animal studies showing that the hyperalgesic ef-
fects of IL-1β, but not IL-8,weremediated by cyclooxygenase-2 (COX-2)
while the hyperalgesic effects of IL-8, but not IL-1β, were mediated by
activation of beta-adrenergic receptors (sympathetic activity) (Cunha
et al., 2005; Verri et al., 2006).
There are indications that the autonomic nervous system forms
an important link for neuro-immune regulation through the cholinergic
anti-inﬂammatory pathway, termed as the inﬂammatory reﬂex (Tracey,
2007). Assessment of heart rate variability (HRV) provides a non-invasive
method to assess autonomic function. Previous studies have reported ab-
normalities in HRV in RA (Janse Van Rensburg et al., 2012) as well as FM
(Meeus et al., 2013) patients. However, to our knowledge, no previous
study has related autonomic tone to CSF patterns of cytokines in chronic
pain patients. In this study, we wanted to proﬁt from our patient cohorts
tomake a direct comparison between patientswith inﬂammatory, COX-2
driven pain (RA) and patients with dysfunctional pain traditionally
regarded as non-inﬂammatory (FM). Our hypothesiswas that RApatients
would have reduced parasympathetic activity which would be related
to elevated CSF IL-1β and that FM patients would have increased sym-
pathetic activity related to elevated CSF IL-8. Also, we extended our
previous CSF assessments with analysis of TNF, IL-4, IL-6, IL-10, CCL-2,
BDNF, NGF as well as the IL-1 receptor antagonist (IL-1Ra) in the FM
patients and with the analysis of CSF IL-8, CCL-2, BDNF, NGF in the RA
patients. In addition to the different concentrations of IL-1β and IL-8,
we hypothesized different CSF proﬁles with higher levels of the pro-
inﬂammatory TNF, IL-6 and CCL-2 and lower concentrations of the
anti-inﬂammatory IL-1Ra, IL-4 and IL-10 in the RA patients compared
to the FM patients.
2. Materials & methods
2.1. Subjects
2.1.1. FM patients
Fifteen female patients (average age 46.2 years, range 25–60 years,
Table 1) participated. They were outpatients at the Department of
Rehabilitation Medicine, Danderyds Hospital, Stockholm and fulﬁlled
the classiﬁcation criteria of the American College of Rheumatology
(ACR) 1990 for ﬁbromyalgia (Wolfe et al., 1990). All the patients had
normal erythrocyte sedimentation rate, hematology count, liver en-
zymes, creatinine kinase, thyroid function, rheumatoid factor and anti-Table 1
Descriptive data for ﬁbromyalgia (FM) patients, rheumatoid arthritis (RA) patients and health
visual analogue scale, MFI-20 =Multidimensional Fatigue Inventory 20 item general, PSQI =
ment = mental components (original 0–100 scoring algorithms based on the summated ratin
Means ± SD FM patients RA pati
Age (years) 46.2 ± 11.1
n = 15
51.1 ±
n = 14
Duration FM/RA (years) 2.9 ± 2.7
n = 15
8.4 ± 8
n = 14
Pain (mm VAS) 65.8 ± 13.2
n = 15
24.0 ±
n = 14
Fatigue (MFI-20) 18.1 ± 1.4
n = 15
14.0 ±
n = 14
Sleep (PSQI) 13.2 ± 3.7
n = 15
6.6 ± 3
n = 13
SF-36phys 26.4 ± 7.6
n = 15
62.4 ±
n = 14
SF-36ment 40.3 ± 21.2
n = 15
72.5 ±
n = 14nuclear antibodies. No medications were taken on a regular basis and
no analgesics or non-steroidal anti-inﬂammatory drugs (NSAIDs) had
been used on the day of assessment. None of the FM patients had
other known painful conditions or neurological diseases.
2.1.2. RA patients
Fourteen female patients (average age 51.1 years, range 36–59 years,
Table 1) participated. Theywere outpatients at the Unit of Rheumatology,
Karolinska University Hospital, Stockholm and fulﬁlled both the 1987 and
2010ACR criteria for RA (Arnett et al., 1988; Aletaha et al., 2010) andnone
fulﬁlled the ACR criteria for ﬁbromyalgia (Wolfe et al., 1990). The average
number (± standard deviation) of swollen and painful joints was 4.9 ±
3.8 and 4.2 ± 3.9 respectively. The average disease activity score for 28
joint count (DAS28)was 3.55±1.3. Twelvepatients (86%) had antibodies
to citrullinated peptide antigens (ACPA) and ten patients (71%) had pos-
itive rheumatoid factor (RF). Sevenpatientswere onmethotrexate (MTX)
monotherapy, twowere onMTX combinedwith etanercept or inﬂiximab,
one was on adalimumab monotherapy, three were on sulfasalazine and
one was on hydroxychloroquine. Three patients were also on low-dose
prednisone (all below 7.5 mg/d). No NSAIDs were administered within
24hbefore CSF sampling andpain and fatigue assessments. No RApatient
had any neurological disease.
2.1.3. Healthy controls
Fifteen healthy sex- and age-matched subjects (average age
44.4 years, range 25–61 years) participated. They were assessed in
the same way as the FM/RA patients except that no lumbar puncture
was performed (for ethical reasons). The subjects were recruited by
advertising at public places at Danderyds Hospital.
The study was approved by the local ethical committee and all the
subjects gave their informed consent to participate. The study followed
the guidelines of the Declaration of Helsinki.
2.2. Procedures
On the ﬁrst day the RA and FM patients and healthy controls
completed all questionnaires and were provided with the device for
HRV assessment. The subjects returned the following morning for
venous and lumbar (patients only) puncture.
2.2.1. Pain ratings and questionnaires
Ongoing pain intensity was rated on a 100 mm visual analogue scale
(VAS) anchored by the words “no pain” and “worst imaginable pain”.
The RA and FM patients and healthy controls rated fatigue (Multidimen-
sional Fatigue Inventory (MFI-20)) (Lin et al., 2009), sleep disturbance
(Pittsburg SleepQuality Inventory (PSQI)) (Buysse et al., 1989) andhealthy controls. SD = standard deviation, NA = non-applicable, NS = non-signiﬁcant, VAS =
Pittsburg Sleep Quality Inventory, SF-36 = Short Form-36; phys = physical components;
g method).
ents Healthy controls Group differences
7.2 44.4 ± 10.7
n = 15
NS
.7 NA p b 0.028
18.0 NA p b 0.001
4.2 5.1 ± 1.0
n = 15
p b 0.001
.0 1.8 ± 1.7
n = 15
p b 0.001
18.6 97.5 ± 2.7
n = 15
p b 0.001
21.6 90.4 ± 6.3
n = 15
p b 0.001
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et al., 2009).2.2.2. Lumbar puncture and cytokine measurements in CSF and serum
Lumbar puncturewas performedwithin 24 h after questionnaires. CSF
was sampled in polypropylene tubes. CSF samples were immediately
centrifuged and supernatants were frozen and stored in−80 °C until
use. Cytokine levels in CSF and serum were analyzed with enzyme-
linked immunosorbent assay (ELISA) (R&D, high sensitivity Quantikine).
Sensitivity, expressed as the mean of minimum detectable dose (MDD),
for the ELISA kits were as follows: IL-1β 0.14 pg/mL; IL-1ra: 6.26 pg/mL;
IL-4: 0.11 pg/mL; IL-6 0.039 pg/mL; IL-8 3.5 pg/mL; IL-10 0.09 pg/mL;
and TNF 0.106 pg/mL. Human CSF was tested for CCL-2 (Cat No
L451AYA-1), BDNF (Cat No N45ZA-1), and β-NGF (custom made proto-
type), in a chemiluminescence assay based on the MSD technology
(Mesoscale Discovery, Gaithersburg,MA, US). The sampleswere captured
on the pre-coatedMSD plates andwere detected using a labeled biotinyl-
ated antibody directed towards the analyte of interest.2.2.3. Autonomic activity and heart rate variability
Holter electrocardiography (ECG) was applied for 24 h measure-
ments during day and sleep at night. Recordings were manually read,
and readings with a high number of ectopic beats were discarded
from analysis. The normal-to-normal R–R interval (NN interval) was
utilized to perform computation of HRV measures from time and fre-
quency domains. In the time domain analysis heart rate, the square
root of the mean of the squares of differences between adjacent NN in-
tervals (RMSSD) and standard deviation of the NN intervals (SDNN)
represent the major components of the time domain HRV (Malik
et al., 1996) and were selected for the statistical analysis. The
power spectrum can be divided into three frequency bands of very
low frequency (VLF) 0.003–0.04 Hz, low frequency (LF) 0.04–0.15 Hz
and high frequency (HF) 0.15–0.4 Hz. Of these, LF and HF can be related
to the controlled and balanced behavior of the two branches of the auto-
nomic nervous system. The efferent vagal activity is amajor contributor to
theHF component, whereas themajor autonomic input on the LF compo-
nent is not entirely clear. It is considered to be contributed by either sym-
pathetic input only, or in some conditions to reﬂect a mixture of both
sympathetic and parasympathetic inputs (Malik et al., 1996). The LF/HF
ratio is related to the sympathetic/parasympathetic balance (Malik et al.,
1996).2.3. Statistics
Overall group differences were analyzed by Kruskal–Wallis test and
post hoc group differences were assessed by independent samples
Mann–Whitney U-test. Correlations were analyzed by Spearmans' cor-
relation coefﬁcient. p b 0.05 was considered as a statistically signiﬁcant
difference. Means and standard deviations are presented in the text.3. Results
3.1. Subject characterization
The FMpatients rated higher ongoing pain intensity (VAS) (p b 0.001)
compared to the RA patients. Furthermore, compared to the RA patients
and healthy controls, the FM patients reported higher ratings of fatigue
(RA; p b 0.002, controls; p b 0.001), sleep disturbance (RA and controls;
p b 0.001) and lower ratings of quality of life (mental and physical) (RA
and controls; p b 0.001). Compared to healthy controls, the RA patients
had higher ratings of fatigue (p b 0.001), sleep disturbance (p b 0.001)
and lower quality of life (SF-36: mental p b 0.014, physical p b 0.001)
(Table 1).3.2. Serum concentrations of cytokines/chemokines
The serum concentrations (mean and standard deviations) are pre-
sented in Table 2. There were statistically signiﬁcant (Kruskal–Wallis
test) overall group differences for TNF (p b 0.001), IL-1β (p b 0.001)
and IL-8 (p b 0.001), but only a tendency for IL-6 (p = 0.054). Post
hoc comparisons revealed signiﬁcantly lower TNF and IL-1β serum con-
centrations in both patient groups compared to healthy controls
(p b 0.05). The RA patients had lower serum concentrations of TNF
(p b 0.006) and IL-1β (p b 0.001) compared to the FM patients. In con-
trast, the FM patients had higher serum IL-8 concentrations compared
to the RA patients (p b 0.001) and healthy controls (p b 0.02), and the
RA patients had lower serum IL-8 levels compared to healthy controls
(p b 0.002). Although the overall group difference was not statistically
signiﬁcant post hoc comparisons, as expected, revealed higher serum
IL-6 levels in the RA patients compared to healthy controls (p b 0.029).
3.3. Cerebrospinal ﬂuid concentrations of cytokines/chemokines
One FMCSF samplewas lost due to technical failure and therefore 14
samples were analyzed. The CSF concentrations (mean and standard
deviations) are presented in Table 3. Compared to the FM patients, the
RA patients had signiﬁcantly higher CSF IL-1β, but lower IL-1Ra. The
reverse was true for IL-8, with higher levels in the FM patients com-
pared to the RA patients. In addition, the FM patients had higher CSF
IL-4 and IL-10 levels compared to the RA patients. Although not statisti-
cally signiﬁcant, the FM patients also tended to have higher CSF TNF
concentrations. There were no signiﬁcant group differences in CSF IL-6
or CCL-2. CSF BDNF and NGF levels were below detection limit in all
the FM and RA patients.
3.4. Relationships between serum and CSF levels of cytokines/chemokines
CSF concentrations of IL-1β and IL-8 were higher than correspond-
ing serum concentrations in the FM (IL-1β p b 0.002; IL-8 p b 0.001)
and RA (IL-1β p b 0.007; IL-8 p b 0.004) patients. TNF was higher
in serum compared to CSF in the FM (p b 0.001) and RA patients
(p b 0.001). There were no statistically signiﬁcant differences between
CSF and serum IL-6 concentrations in either group. Therewere no statis-
tically signiﬁcant correlations between serum and CSF concentrations
for any of the assessed cytokines/chemokines.
3.5. Autonomic activity in patients and controls
Overall group differences concerning time and frequency domain
HRVparameters are presented in Table 4. All three time-domain param-
eters differed signiﬁcantly between RA and controls, and FM and con-
trols, respectively. There was a decrease in HF in RA compared to
controls, in line with decreased parasympathetic activity in RA. In FM
therewas a signiﬁcantly increased ratio LF/HF, in linewith increased sym-
pathetic activity. There were no statistically signiﬁcant differences be-
tween RA and FM in either time- or frequency domain HRV parameters.
3.6. Relationship between autonomic activity and cytokine levels
Concerning time-domain HRV parameters, there was a strong
negative correlation between serum IL-6 levels in RA and SDNN
(r = −0.868 p b 0.0001). Moreover, SDNN in RA correlated negatively
with CSF levels of IL-10 (r=−0.716, p b 0.006), and also serum IL-1beta
in FM and SDNN was signiﬁcantly correlated (r = 0.646 p b 0.01). There
were no other correlations between CSF/serum cytokines and the time-
domain HRV parameters.
The frequency domain of HRV is known to reﬂect sympathetic/
parasympathetic balance. In RA, CSF IL-1β correlated positively with
LF/HF (r = 0.64; p b 0.05). Moreover, and in line with these data, RA
CSF IL-10 correlated negatively with LF (r =−0.58; p b 0.05). On the
Table 2
Serum cytokine and chemokine concentrations in ﬁbromyalgia (FM) patients, rheumatoid
arthritis (RA) patients and healthy controls. Overall group differences are shown. Statistically
signiﬁcant differences between FM and RA patients are marked † and signiﬁcant differences
between controls and patients are marked ‡. p b 0.05 is regarded as a statistically signiﬁcant
difference. SD = standard deviation. IL = interleukin, TNF = tumor necrosis factor.
Serum levels
(pg/mL)
Means ± SD
FM RA Controls Group
differences
IL-1β 0.59 ± 0.08‡
n = 15
0.02 ± 0.06†‡
n = 13
0.83 ± 0.24
n = 15
p b 0.001
IL-8 21.36 ± 5.54‡
n = 15
10.42 ± 6.68†‡
n = 12
16.58 ± 6.20
n = 15
p b 0.001
TNF 2.77 ± 1.61‡
n = 14
1.41 ± 0.96†‡
n = 13
4.42 ± 2.29
n = 15
p b 0.001
IL-6 1.45 ± 0.76
n = 14
7.50 ± 16.07‡
n = 14
1.21 ± 0.70
n = 15
p = 0.054
Table 4
Time and frequency domains of heart rate variability (HRV) inﬁbromyalgia (FM) patients,
rheumatoid arthritis (RA) patients and healthy controls. Overall group differences
are shown. Statistically signiﬁcant differences between patients and controls are marked
‡. SD = standard deviation. Bpm = beats per minute, RMSSD = the square root of the
mean squared differences between adjacent NN intervals, SDNN= the standard deviation
of the NN interval, NN interval = the normal-to-normal interval; all intervals between
adjacent QRS complexes resulting from sinus node depolarizations, LF = low frequency
power; HF = high frequency power; LF/HF = ratio LF (ms2)/HF (ms2).
Means ± SD FM RA Healthy
controls
Group
differences
Heart rate (bpm) 78 + 10‡
n = 15
75 + 6‡
n = 14
68 + 5
n = 15
p = 0.003
RMSSD (ms) 30.9 + 12.2‡
n = 15
29.2 + 8.1‡
n = 14
50.7 + 24.8
n = 15
p = 0.002
SDNN 124 + 24.9‡
n = 15
127.8 + 27.6‡
n = 14
152.9 + 33.0
n = 15
p = 0.02
LF 836 + 541
n = 15
530 + 213‡
n = 13
948 + 523
n = 15
NS
HF 410 + 259
n = 15
313 + 280‡
n = 13
759 + 657
n = 15
p = 0.018
LF/HF 3.41 + 1.30‡
n = 15
2.65 + 0.71
n = 13
2.23 + 1.0
n = 15
p = 0.036
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cytokines and HRV were found. In serum, IL-1β and IL-10 in the RA
patients was not correlated to HRV, but serum IL-6 was correlated
inversely to LF both in RA (r = −0.55 p b 0.05) and controls
(r = −0.46; p b 0.05). There were no correlations between CSF IL-
6 or other CSF or serum cytokine levels and frequency domains of
HRV in the RA and FM patients.
4. Discussion
In accordance with our a priori hypothesis, the RA patients had a
reduced parasympathetic tone compared to controls and an inverse
correlation between CSF IL-1β levels and parasympathetic activity.
Compared to controls, the FM patients had increased sympathetic activ-
ity, but contrary to our hypothesis, we did not ﬁnd a positive correlation
between CSF IL-8 and HRV measures of sympathetic tone. The RA pa-
tients had higher CSF concentrations of the pro-inﬂammatory IL-1β
and lower anti-inﬂammatory IL-1Ra, IL-4 and IL-10 compared to the
FM patients, whereas the FM patients had higher CSF levels of the pro-
inﬂammatory chemokine IL-8 compared to the RA patients. Thus we
found evidence of different CSF cytokine proﬁles in the patients with in-
ﬂammatory, COX-2 dependent pain (RA) and dysfunctional, possibly
sympathetically mediated pain (FM). The CSF concentrations of IL-1β
and IL-8 were signiﬁcantly higher than serum concentrations in both
groups indicating a central inﬂammatory response involving these
cytokines.Table 3
Concentrations of cytokines and chemokines in cerebrospinal ﬂuid (CSF) of ﬁbromyalgia
(FM) and rheumatoid arthritis (RA) patients. Overall group differences are shown. p b
0.05 is regarded as a statistically signiﬁcant difference. SD = standard deviation. IL =
interleukin, TNF = tumor necrosis factor, CCL-2 = chemokine (C–C motif) ligand 2,
IL-1Ra = interleukin 1 receptor antagonist.
CSF levels (pg/mL)
Means ± SD
FM RA Group differences
IL-1β 2.58 ± 1.98
n = 14
8.83 ± 7.21
n = 14
p = 0.002
IL-8 62.35 ± 26.26
n = 14
26.92 ± 14.07
n = 12
p b 0.001
TNF 0.38 ± 0.22
n = 14
0.26 ± 0.09
n = 14
NS (p = 0.056)
IL-6 1.80 ± 0.69
n = 14
1.60 ± 0.73
n = 14
NS
CCL-2 439.03 ± 114.54
n = 12
491.43 ± 134.74
n = 13
NS
IL-1Ra 27.50 + 4.96
n = 14
17.06 + 9.82
n = 14
p = 0.002
IL-4 0.25 + 0.20
n = 14
0.04 + 0.05
n = 14
p b 0.001
IL-10 0.43 + 0.19
n = 14
0.13 + 0.08
n = 14
p b 0.001An important link for neuro-immune regulation is the cholinergic
anti-inﬂammatory pathway, termed as the inﬂammatory reﬂex, which
has been shown to impact immune regulation in experimental inﬂam-
matory conditions and arthritis (Tracey, 2007). Moreover, these vagus-
mediated neuro-immune mechanisms have also been shown to be
dysfunctional in several inﬂammatory diseases including RA (Tracey,
2007). In the present study, we could conﬁrm a decreased vagus activity
in RA, with a marked decrease in HF. It has been discussed how much
peripheral inﬂammationmay inﬂuence the parasympathetic dysfunction
in RA and a relation to inﬂammatory state was indicated by the coupling
between parasympathetic dysfunction and clinical response to anti-TNF
therapy (Holman and Ng, 2008). Whereas the peripheral inﬂammatory
reﬂex is dependent upon activation of the alpha7 nicotinic receptor
(Tracey, 2007), CNS activation of the efferent, cholinergic vagus nerve is
mediated throughmuscarinic receptors (Pavlov et al., 2006). Interesting-
ly, earlier investigations have shown that interleukin IL-1β may cause
dysfunction in cholinergic neurotransmission (Schliebs et al., 2006).
Thus, our ﬁndings of an inverse correlation between elevated IL-1β levels
in RA CSF and parasympathetic activity may indicate that autonomic ac-
tivity in RA is centrally regulated through action of inﬂammatory cyto-
kines, such as IL-1β.
Interestingly, and in the RA patients only, we found an inverse corre-
lation between intrathecal levels of the anti-inﬂammatory cytokine IL-
10 and LF.Whereas themajor autonomic component of LF is not exactly
clear, LF has in some studies been related directly to sympathetic activ-
ity. Thus, in a post-infarction study beta-blockers were shown to reduce
LF, stressing the importance of adrenergic stimulation for this compo-
nent of HRV (Sandrone et al., 1994). In addition, central nervous sympa-
thetic outﬂow and intracerebral cathecolamine release has been shown
related to action of inﬂammatory cytokines (Szelenyi and Vizi, 2007),
and it is possible that intrathecal IL-10may thus have a regulating func-
tion in this context. When correlating the serum levels of cytokines to
HRV, we found an inverse correlation between serum IL-6 and LF in
both RA and controls. This pattern has earlier been described in healthy
controls (von Känel et al., 2008), and conﬁrms the association of sys-
temic inﬂammation in relation to autonomic activity also under physio-
logical conditions.
In FM, we detected an increased sympathetic-to-parasympathetic
balance, which is well in line with previous data (Meeus et al., 2013),
however, no correlation was found between cerebrospinal cytokines/
chemokines and HRV. The fact that we failed to conﬁrm a statistically
signiﬁcant correlation between CSF IL-8 and HRV measures of sympa-
thetic activity in our FM cohort should be interpreted with caution
due to the small sample size. Previously, pain and stress have been
53E. Kosek et al. / Journal of Neuroimmunology 280 (2015) 49–55directly associated with increased central nervous sympathetic outﬂow
(Li et al., 1996). Furthermore, in animal studies stress and activation of
sympathetic NS have been reported to increase the release of the IL-8
analogue CINC-1 from the hypothalamic–pituitary region (Sakamoto
et al., 1996;Matsumoto et al., 1997). The combination of elevated stress
levels (Schmidt-Wilcke and Clauw, 2011) and autonomic dysfunction
(Meeus et al., 2013) is in line with the proposal to regard FM as a
sympathetically mediated pain syndrome (Martinez-Lavin, 2007). The
latter is in agreement with our ﬁndings of higher CSF and serum IL-8
in the FM patients compared to the RA patients and also the increased
sympathetic activity in the FM patients, but not the RA patients, com-
pared to controls.
The different CSF cytokine patterns, i.e., higher CSF IL-1β and lower
anti-inﬂammatory IL-1Ra, IL-4 and IL-10 in an inﬂammatory painful
condition (RA) and higher CSF and serum IL-8 in a dysfunctional pain
syndrome (FM) tally reports from animal studies showing that the
two pro-inﬂammatory cytokines IL-1β and IL-8 contribute to pain and
hyperalgesia by different mechanisms (Cunha et al., 1991; Sachs et al.,
2002). Administration of IL-1β in peripheral tissues or intrathecally
stimulates COX-2 activity (Bartfai, 2001; Samad et al., 2001) and IL-1β
mediated increase in pain sensitivity can be prevented by COX-2 in-
hibitors (Cunha et al., 1991; Sachs et al., 2002; Samad et al., 2001). Phar-
macological agents counteracting the biological effects of IL-1β (in the
form, of anakinra, IL-1Ra) have been established in the treatment of
RA (Nam et al., 2010; Neurath and Finotto, 2011) and COX-2 inhibitors
have shown good pain relieving effects (Shi and Klotz, 2008). In contrast,
administration of IL-8 (or the rat analogue CINC-1) in peripheral tissues or
intrathecally causes an increase in pain sensitivity (Yamamoto et al.,
1998; Bartfai, 2001; Oh et al., 2001; Ahn et al., 2005) that can be reversed
by beta-adrenergic receptor antagonists (Ahn et al., 2005) or guanethi-
dine (Cunha et al., 1991) but not COX-2 inhibitors (Ahn et al., 2005),
which ﬁts well with the inefﬁcacy of COX-2 inhibitors in FM (Carville
et al., 2008). Contrary to our hypothesis, we found no group difference re-
garding CSF CCL-2. Despite the fact that CCL-2 has been implicated in the
activation of astrocytes, promoting their release of IL-1β (Gao and Ji,
2010)we found no evidence that this would be themechanism responsi-
ble for the elevated CSF IL-1β in our RA patients.
The RA patients had higher serum IL-6 compared to healthy controls
(but not the FM patients) and there was a positive correlation between
serum IL-6 levels and disease activity assessed by DAS28 (r = 0.585,
p = 0.028), as reported previously (Madhok et al., 1993; Nishimoto
et al., 2004, 2007). However, all the RA patients in the present study
were on DMARD medications, which might have inﬂuenced the serum
levels of pro-inﬂammatory cytokines (Eklund et al., 2007; Chen et al.,
2011) and could explain the lower TNF, IL-1β and IL-8 serum concentra-
tions compared to the healthy controls and the FM patients. Only serum
IL-8 levelswere higher in our FMpatients compared to healthy controls,
which is in accordance with other studies (Wallace et al., 2001; Gur
et al., 2002; Bazzichi et al., 2007; Wang et al., 2009; Ortega et al.,
2009; Kadetoff et al., 2012).
Despite the fact that cytokine/chemokine production is differentially
regulated in the peripheral and central compartments (Feldmann and
Maini, 2008), the compartments are integrated, thus cytokine/chemokine
levels in one compartment inﬂuence the concentrations in the other com-
partment (Szelenyi and Vizi, 2007). Our ﬁndings of higher IL-1β and IL-8
concentrations in the CSF compared to serum as well as the lack of corre-
lations between the CSF and serum levels in both groups does not favor
simple transport or leakage of the cytokines across the blood–brain-
barrier (BBB) (Gutierrez and Kastin, 1993; Banks et al., 1995; Watkins
et al., 1995; Quan and Herkenham, 2002). Rather our data would indi-
cate central cytokine/chemokine production. Notably, circulating cyto-
kines can affect the CNS indirectly by activating the brain endothelium
to produce pro-inﬂammatory cytokines (Reijerkerk et al., 2012),
such as IL-1β (Szelenyi, 2001) or IL-8 analogue (Zidovetzki et al.,
1999; Chen et al., 2001) thus permitting the signal to be transduced
from the blood stream into the CNS without the need to cross theBBB (Szelenyi, 2001). In addition, peripheral injections of pro-
inﬂammatory cytokines/chemokines have the potential to activate
glia cells (Watkins and Maier, 2005) and activated glia can produce
IL-1β in response to inﬂammatory stimuli (Pinteaux et al., 2002; Guo
et al., 2007) and also have the potential to produce IL-8 (Milligan and
Watkins, 2009). Our results indicate that the pattern of the release of
pro-inﬂammatory substances in the CNS could reﬂect peripheral inﬂam-
matory mechanisms, and thus result in speciﬁc patterns for different
conditions.
While the communication between peripheral tissues and CNS is
well established, the reverse, i.e., if central inﬂammation mediated
by activated glia or neurons affects efferent signaling remains highly
speculative. However, the inverse correlation between CSF IL-1β and
parasympathetic activity in our RA patients, as well as the symmetric dis-
tribution of arthritis in RA with reports of remission of RA in hemiparetic
limbs following ischemic cerebral infarcts (Keyszer et al., 2004), suggests
that also an efferent communication, i.e., CNS to peripherymight be of rel-
evance. The concentrations of TNFwere higher in the serum than in CSF in
both groups and IL-6 levels were not statistically different between the
serum and CSF in either group. The lack of signiﬁcant up-regulation of
these pro-inﬂammatory cytokines in CSF compared to the serum is in
line with previous data demonstrating low levels of these cytokines in
CNS (Vladic et al., 2002).
4.1. Limitations
The present study suffers from several limitations. For ethical
reasons we had to keep to a low number of subjects in the patient
groups and we had no healthy CSF controls. Furthermore, patients
were recruited from specialized clinics and thusmay not be representa-
tive for FMor RApopulations as such. For ethical reasons the RApatients
could not be taken off DMARDS, which most likely affected the serum
assessments and possibly also the CSF through indirect mechanisms.
Furthermore, the serum samples were not available to compare
IL-1Ra, IL-4, IL-10 and CCL-2 in all groups.
5. Conclusions
In conclusion, we found differential CSF cytokine proﬁles with
higher IL-1β and lower IL-1Ra, IL-4 and IL-10 in the CSF of the RA
patients, compared to FM and higher IL-8 in the CSF of the FM patients
compared to RA. Our results indicate different proﬁles of central cyto-
kine release, i.e., IL-1β in the patients with inﬂammatory, prostaglandin
associated pain (RA) and IL-8 in the patients with dysfunctional, possibly
sympathetically mediated pain (FM). Furthermore, RA was associated
with decrease in vagus activity, which correlated with elevated cerebral
IL-1β levels in accordance with the cholinergic anti-inﬂammatory
pathway, whereas autonomic disturbances in FM were characterized by
sympathetic over-activity but did not correlate to the CSF IL-8 levels.
Further studies assessing the usefulness of pro-inﬂammatory cytokines
for diagnostic purposes and to increase the understanding of chronic
pain mechanisms are needed. Our results indicate that a bi-directional
communication between peripheral tissues and CNS involving the im-
mune system and glia could be of outmost importance in chronic pain
conditions. Increased understanding of these mechanisms could open
up for truly new treatment approaches.
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